ArticleCell discovery2020
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
Article in Cell discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 855 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy Study of Ruxolitinib in the Treatment of Severe Acute Respiratory Syndrome Due to SARS-COV-2
Efficacy and Safety of Sirolimus for Treating COVID-19 Infection
Who cites it
855 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,701 citations in OpenAlex.
- Efficacy of tenofovir on clinical outcomes of COVID-19 patients: a systematic review.BMC infectious diseases · 2025Pooled it
- Pneumolysin as a target for new therapies against pneumococcal infections: A systematic review.PloS one · 2023Pooled it
- Drug repositioning: Progress and challenges in drug discovery for various diseases.European journal of medicinal chemistry · 2022Pooled it
- Safety and efficacy of sirolimus in hospitalised patients with COVID-19 pneumonia.Respiratory investigation · 2024Trial
- Biological Rhythms in Coronavirus Pneumonia Pathogenesis.Journal of biological rhythms · 2026Article
- Article
- The molecular ICU: a primer on omics, informatics and the future of precision critical care.Critical care (London, England) · 2026Review
- A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).CPT: pharmacometrics & systems pharmacology · 2026Review
- CLC-Pred Synergy: Web Application for Predicting Pairwise Drug Combinations with Synergistic Activity Against NCI60 Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Systems biology-based drug repurposing for neuroinflammation treatment in activated human microglia.Scientific reports · 2026Article
- Standardizing antiviral response metrics for mono- and combination therapies in acute, chronic and latent viral infections.Virology journal · 2026Review
- Interactys-AI: Toward AI-Driven Structural Mapping of Virus-Host Interfaces for Antiviral Repurposing and Pandemic Preparedness.Biomolecules · 2026Review
- Tea Polyphenols in the COVID-19 Era: Mechanistic Insights and Translational Challenges.Current issues in molecular biology · 2026Review
- Paeoniflorin Modulates TREM-1/NF-κB/LXRα/ABCG1 Pathway to Improve Cholesterol Metabolism and Inflammation in Hyperlipidemic Rat.International journal of molecular sciences · 2026Article
- In silico structural and functional characterization of high-risk missense variants in MMP8, GZMK, and OASL genes associated with epidemic viral infections.Scientific reports · 2026Article
- Cell type-specific gene regulatory atlas prioritizes drug targets and repurposable medicines in Alzheimer's disease.Genome research · 2026Article
- Unlocking the potential of computational phenotypic drug discovery: methods, challenges, and future directions.NPJ systems biology and applications · 2026Review
- From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing.Frontiers in pharmacology · 2026Article
- Severity-dependent metabolic rewiring in COVID-19 based on untargeted metabolomic profiling of patient plasma.PloS one · 2026Article
- Artificial Intelligence to Guide Repurposing of Drugs.Annual review of medicine · 2026Review
795 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the "
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.